Likewise, PARP1, a DNA binding protein associated with DNA damage repair that confers resistance to genotoxic compounds routinely used as chemotherapeutic agents(Hu et al. 2018), was also noted to decline in DLBCL cells. This evidence concerns the gene PARP1 and diffuse large B-cell lymphoma.